Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207015 | 0.81 | MAPT (0.41) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5208991 | 0.81 | MAPT (0.39) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5777020 | 0.81 | MAPT (0.42) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5211936 | 0.81 | MAPT (0.42) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5207462 | 0.79 | MAPT (0.41) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5772629 | 0.79 | MEN1 (0.46) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL4837046 | 0.79 | HTR2A (0.39) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5207665 | 0.78 | HTT (0.49) | MAPTMEN1KMT2ALMNAGLA | |
| SCHEMBL5208383 | 0.78 | SMO (0.43) | MAPTMEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL5207600 | 0.77 | TP53 (0.44) | MAPTMEN1KMT2ALMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | MAPT 4701/4885MEN1 2811/4885KMT2A 3907/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | MAPT 4763/4885MEN1 2072/4885KMT2A 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.